Genomic alterations as potential therapeutic targets in extramammary Paget’s disease of the vulva Journal Article
| Authors: | Stasenko, M.; Jayakumaran, G.; Cowan, R.; Broach, V.; Chi, D. S.; Rossi, A.; Hollman, T. J.; Zehir, A.; Abu-Rustum, N. R.; Leitao, M. M. Jr |
| Article Title: | Genomic alterations as potential therapeutic targets in extramammary Paget’s disease of the vulva |
| Abstract: | PURPOSE To identify genomic alterations as potential therapeutic targets in extramammary Paget disease (EMPD) of the vulva. METHODS We identified all patients with primary vulvar EMPD who were treated at our institution and underwent paired tumor-normal massively parallel sequencing of 410-468 cancer-related genes (MSK-IMPACT assay). EMPD of the vulva samples sequenced from 2014 to 2019 were reviewed and somatic mutations identified, with specific focus on mutations of potential therapeutic targets. Clinical data were abstracted from electronic medical records. Microsatellite instability (MSI) was assessed by MSIscore. RESULTS Tumors of 26 patients with EMPD underwent genomic sequencing. At diagnosis, all patients had noninvasive or microinvasive (, 1 mm) disease; invasive disease eventually developed in 2 patients. Primary treatment was surgery for 19 patients (73%) and imiquimod topical therapy for 7 (27%). Seven patients had ≥ 2 surgeries as part of clinical course (1 patient had 5 vulvar resections). Samples had a median of 2 coding mutations in the genes analyzed (range, 0-29). The most common mutations were in PIK3CA (n = 9; 35%), ERBB2 (4 mutations and 3 copy number alterations; 27%), and TP53 (n = 7; 27%). MSIscore was available for 23 samples; all were microsatellite stable. After tumor genomic profiling, a patient who was initially treated with multiple resections and imiquimod was found to have a PIK3CA p.E542K mutation. She underwent PI3Kinhibitor treatment for 18 months before disease progression. CONCLUSION EMPD of the vulva has a chronic and relapsing course, often requiring multiple surgical resections. Effective topical treatments are lacking. We identified targetable mutations (PIK3CA or ERBB2) in . 25% of a real-world clinical cohort. Additional prospective research implementing targetable therapies for EMPD treatment is warranted. © 2020 by American Society of Clinical Oncology |
| Journal Title: | JCO Precision Oncology |
| Volume: | 4 |
| ISSN: | 2473-4284 |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2020-09-15 |
| Start Page: | 1054 |
| End Page: | 1060 |
| Language: | English |
| DOI: | 10.1200/po.20.00073 |
| PROVIDER: | scopus |
| PMCID: | PMC7529529 |
| PUBMED: | 33015527 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 2 November 2020 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
-
710Chi -
576Leitao -
890Abu-Rustum -
344Zehir -
236Rossi -
126Hollmann -
32Cowan -
116Broach -
45Jayakumaran -
20Stasenko
Related MSK Work